The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.

Source:http://linkedlifedata.com/resource/pubmed/id/9139880

Int. J. Cancer 1997 May 2 71 3 429-35

Download in:

View as

Triples

General Info

PMID
9139880